The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of PfArk1 and Hemozoin Formation
The human Chk1 inhibitor CHIR-124 exhibits broad-spectrum antimalarial activity against various stages of *Plasmodium falciparum*, including drug-resistant strains, through a polypharmacological mechanism that simultaneously inhibits the essential kinase PfArk1 and disrupts hemozoin formation.